In order to raise venture capital, Dou Qiling and Ye not only joined several partners, but also mortgaged their own house, borrowed more than 200,000 yuan from the bank and raised 350,000 yuan with their own savings. The first product produced by the pharmaceutical factory is Keke capsule, and the first year's sales revenue is170,000 yuan.
In 2000, after successfully completing the shareholding system reform, Baiyi Pharmaceutical was successfully listed on the Shanghai Stock Exchange on March 8, 2004, which is also the first private enterprise listed in Guizhou Province.
However, in 2009, Ye and Dou Qiling "separated" due to emotional breakdown, and Ye received 97.02% equity of Shanghai Baijiayi Pharmaceutical Co., Ltd. (predecessor of Jingfeng Medicine) for 99.03 million yuan. Since then, Baiyi Pharmaceutical has been completely taken over by Ye's ex-wife Dou Qiling. Ye built Jingfeng Medicine through backdoor and became a competitor with his ex-wife Dou Qiling.
At the same time that her career returned to its peak, Ye married Zhang Hui, a post-80s "wife" who was similar to her daughter's age. The age difference between them is 29 years. However, the second marriage did not last forever, and the two divorced on 20 19.
After the second marriage broke down, the performance of Jingfeng Medicine founded by Ye began to change face, and then it declined all the way. During the COVID-19 epidemic, the company also produced epidemic prevention products, and even looked for projects such as vaccine research and development, but all ended in vain.
Similarly, Baiyi Pharmaceutical, which experienced a high-light moment, seems to be going downhill in recent years. The company's shareholders used the raised funds to buy furniture, and the credit rating was reduced to a minimum. Moreover, according to the website of the Shanghai Stock Exchange, the company has been publicly condemned by the Shanghai Stock Exchange for six times in the past five years and given a written warning to informed criticism, involving controlling shareholders, directors and chief financial officers. Moreover, after the impairment of goodwill and the slowdown of mergers and acquisitions, the company's revenue scale is also declining.